Long-term follow-up results from JAVELIN Merkel 200 and KEYNOTE-017 in MCC
Paul Nghiem, MD, PhD, University of Washington Medical Center, Seattle, WA, discusses the updated results of the JAVELIN Merkel 200 (NCT02155647) and KEYNOTE-017 (NCT02267603) trials. JAVELIN Merkel 200 investigated the efficacy of avelumab in patients with previously treated merkel cell carcinoma (MCC). After five years of follow-up, trial data shows that avelumab monotherapy led to meaningful long-term overall survival in a subset of patients with MCC whose disease had progressed after chemotherapy and supports its role as a standard of care treatment option. The Phase II multicenter KEYNOTE-017 study assessed first-line pembrolizumab for advanced MCC. With three-year survival data, this trial represents the longest available follow-up of any first-line anti-PD-1/PD-L1 therapy in MCC and demonstrates durable progression-free survival and overall survival in a proportion of patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
-
Category
![Kinnggloyalty ~ lit|trap|follow [DR kinggg god] [Prod.Dtrf) [official video]](https://i.ytimg.com/vi/hZRIXYBLeqo/mqdefault.jpg)
No comments found